October 12, 2023 News by Patricia Inacio, PhD Vidofludimus calcium reduced NfL levels in progressive MS patients Vidofludimus calcium (IMU-838), an investigational oral therapy being developed byĀ Immunic Therapeutics for all types of multiple sclerosis (MS), has demonstrated neuroprotective effects in people with progressive forms of the disease, interim clinical trial data show. The experimental therapy was associated with reductions in neurofilament light chain (NfL)…
June 2, 2023 News by Marisa Wexler, MS Vidofludimus calcium tolerated well for nearly 4 years Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new data from an extension study show. Findings were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, in a poster titled “Assessment of Long-Term Safety…
May 18, 2023 News by Lindsey Shapiro, PhD Experimental MS therapy vidofludimus calcium triggers Nurr1 protein Vidofludimus calcium (IMU-838), an investigational multiple sclerosis (MS) therapy with promising results in clinical trials, may exert neuroprotective effects by activating a protein called Nurr1, according to newly published preclinical data. The observed actions on Nurr1 are in addition to the therapy’s known role as an inhibitor of…
June 17, 2022 News by Marisa Wexler, MS Vidofludimus Calcium Safely Reduced RRMS Brain Lesions Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosisĀ (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at…
January 17, 2022 News by Marta Figueiredo, PhD 1st RRMS Patient Enrolled in ENSURE-2 Trial of Oral IMU-838 The ENSURE-2 Phase 3 clinical trial, evaluating Immunic Therapeuticsā experimental oral therapy IMU-838 (vidofludimus calcium) in adults with relapsing-remitting multiple sclerosis (RRMS), has enrolled its first patient. The milestone, announced in an email to Multiple Sclerosis News Today, follows the recruitment of the first RRMS patient in…
November 24, 2021 News by Marisa Wexler, MS 1st Patient Enrolled in ENSURE Trials of IMU-838 in RRMS Immunic TherapeuticsĀ has enrolled the first participant in its Phase 3 ENSURE clinical trial program, which is testing the company’s investigational treatment IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS). “Enrollment of the first patient in ENSURE … marks an important inflection point for Immunic as we…
October 1, 2021 News by Patricia Inacio, PhD CALLIPER Trial for Progressive MS Enrolls First Patient Immunic Therapeutics has enrolled the first patient in a Phase 2 clinical trial testing its oral therapy candidate IMU-838 for the treatment of progressive multiple sclerosis (MS). The trial, CALLIPER (NCT05054140), is expected to run in parallel to the companyās two identically-designed Phase 3 trials, dubbed…
July 2, 2021 News by Marisa Wexler, MS Trials of IMU-838 in RRMS, Progressive MS Start Later This Year The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medicationĀ IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS), as well as a separate trial for people with progressive types of MS. The RRMS clinical trial program, expected…
November 11, 2020 News by Marta Figueiredo, PhD Additional Group of RRMS Patients Sought to Take Lower Dose of IMU-838 in Phase 2 Trial Immunic Therapeutics is seeking 60 more adults with relapsing-remitting multiple sclerosisĀ (RRMS) to test a lower dose of IMU-838, its leading oral experimental therapy, in its ongoing Phase 2 EMPhASIS trial. The decision was based on previous trial results showing that both doses tested (30 and 45 mg…
August 4, 2020 News by Marisa Wexler, MS Oral RRMS Therapy Safely Lowers Active Lesions in Phase 2 Trial, Data Show Immunic Therapeutics‘sĀ IMU-838, a selective immune system modulator, can safely lower the number of brain lesions in people with relapsing-remitting multiple sclerosisĀ (RRMS), top-line Phase 2 clinical trial data suggest. Findings show the trial met its primary goal with statistical significance ā a reduction inĀ active lesions (gadolinium…
October 15, 2019 News by Ana Pena PhD Immunic Therapeutics Fully Enrolls Phase 2 Trial of Oral IMU-838, Potential RRMS Treatment Immunic TherapeuticsĀ announced that a Phase 2 clinical trial of IMU-838, its experimental oral therapyĀ forĀ relapsing-remitting multiple sclerosis (RRMS), is fully enrolled ahead of schedule. The trial, called EMPhASIS, also exceeded its target number of participants: Immunic set an initial recruitment goal of 195 patients by mid-2020, and enrolled 210…
March 11, 2019 News by Alberto Molano, PhD Immunic Therapeutics Enrolls First Patient in Phase 2 Trial of IMU-838 for RRMS Immunic TherapeuticsĀ has enrolled the first patient in its Phase 2 clinical trial testing IMU-838, a potential oral therapy forĀ relapsing-remitting multiple sclerosis (RRMS). IMU-838 (vidofludimus calcium) is a next-generation selective modulator of the immune system. It works by inhibiting an enzyme called dihydroorotate dehydrogenase (DHODH), which plays a role…